At the time of writing, Abbott Laboratories [ABT] stock is trading at $111.17, down -1.13%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ABT shares have lost -0.10% over the last week, with a monthly amount drifted -7.50%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 2, April 2024, Abbott Receives FDA Approval for TriClip™, First-of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve. In a post published today on Yahoo Finance, TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery.
From an analyst’s perspective:
Abbott Laboratories [NYSE: ABT] stock has seen the most recent analyst activity on July 21, 2023, when Wolfe Research upgraded its rating to a Peer Perform. Previously, Morgan Stanley downgraded its rating to Equal-Weight on May 30, 2023, and kept the price target unchanged to $112. On April 20, 2023, Wolfe Research reiterated its Underperform rating and revised its price target to $103 on the stock. UBS reiterated its Buy rating and increased its price target to $130 on April 20, 2023. Raymond James reiterated its recommendation of a Outperform and raised its price target to $123 on April 20, 2023. JP Morgan reiterated a Overweight rating for this stock on April 20, 2023, and upped its price target to $122. In a note dated April 20, 2023, Bernstein reiterated an Outperform rating on this stock and boosted its target price from $132 to $133.
For the past year, the stock price of Abbott Laboratories fluctuated between $89.67 and $121.64. Currently, Wall Street analysts expect the stock to reach $130.42 within the next 12 months. Abbott Laboratories [NYSE: ABT] shares were valued at $111.17 at the most recent close of the market. An investor can expect a potential return of 17.32% based on the average ABT price forecast.
Analyzing the ABT fundamentals
According to Abbott Laboratories [NYSE:ABT], the company’s sales were 40.11B for trailing twelve months, which represents an 1.49% jump. Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at 0.17%, Pretax Profit Margin comes in at 0.17%, and Net Profit Margin reading is 0.14%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is 0.12 and Total Capital is 0.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.39.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 110.46 points at the first support level, and at 109.74 for the second support level. However, for the 1st resistance point, the stock is sitting at 111.78, and for the 2nd resistance point, it is at 112.38.
Abbott Laboratories [ABT] reported earnings per share of $1.19 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $1.19/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $1.14 per share as compared to estimates of $1.1 per share, a difference of $0.04 representing a surprise of 3.60%.
Ratios To Look Out For
It is important to note that Abbott Laboratories [NYSE:ABT] has a current ratio of 1.64. Further, the Quick Ratio stands at 1.16, while the Cash Ratio is 0.5. Considering the valuation of this stock, the price to sales ratio is 4.81, the price to book ratio is 4.99 and price to earnings (TTM) ratio is 34.04.
Transactions by insiders
Recent insider trading involved Salvadori Daniel Gesua Sive, EXECUTIVE VICE PRESIDENT, that happened on Mar 01 ’24 when 963.0 shares were sold. EXECUTIVE VICE PRESIDENT, ALLEN HUBERT L completed a deal on Mar 01 ’24 to sell 853.0 shares. Meanwhile, EXECUTIVE VICE PRESIDENT Morrone Louis H. sold 801.0 shares on Mar 01 ’24.
